Archives
-
PD98059: Turning MEK Inhibition Into Translation
2026-09-05
A translational framework for using PD98059 to connect MEK/ERK signaling with cell-cycle control, apoptosis, oxidative injury, and neuroprotection while keeping model maturity and experimental limitations in view.
-
LY294002 in Fibrosis Pathway Dissection
2026-09-04
LY294002 is more than a generic PI3K blocker: it can serve as a reversible pathway probe for connecting TGF-β1, PI3K/Akt signaling, lncRNA regulation, and collagen deposition. This article translates pulmonary fibrosis findings into practical assay-design decisions while defining the compound’s specificity limits.
-
NU7441 (KU-57788) DNA Repair Workflow
2026-09-04
NU7441 (KU-57788) provides a potent, ATP-competitive way to interrogate DNA-PK function in DNA repair research, cell-cycle studies, and cancer models. This practical guide connects selective pharmacology with the miR-375/PRKDC/PD-L1 findings reported in gastric cancer, while emphasizing controls, dosing logic, and troubleshooting.
-
KU-60019: Strategic ATM Inhibition in Glioma
2026-09-03
A translational perspective on KU-60019 as a selective ATM kinase inhibitor for glioma radiosensitization, invasion studies, experimental design, and hypothesis-led biomarker development.
-
LC-MS/MS Maps Carbapenemase Resistance
2026-09-03
A 2025 study used LC-MS/MS metabolomics and supervised machine learning to distinguish carbapenemase-producing Enterobacterales from non-CPE isolates under antibiotic-free conditions. Its biomarker and pathway findings suggest a route toward faster resistance detection while also clarifying the metabolic systems associated with the CPE phenotype.
-
IAM LC vs LEKC for Pulmonary Drug Permeability
2026-09-02
This Journal of Chromatography A study provides a direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography for biomimetic drug–membrane partitioning and pulmonary permeability assessment. LEKC more closely modeled apparent lung permeability through combined hydrophobic and electrostatic interactions, whereas IAM LC offered broader analyte coverage and simpler high-throughput implementation.
-
Reelin Signaling Enables Ketamine’s Synaptic Effects
2026-09-02
The 2021 PNAS study identifies Reelin–Apoer2–SFK signaling as a permissive requirement for ketamine-induced hippocampal plasticity and behavioral responses. By combining genetic deletion, pharmacological inhibition, electrophysiology, and biochemical analysis, the authors show that preserved baseline NMDA receptor function—not an acute increase in DAB1 phosphorylation—is central to ketamine sensitivity.
-
Aconitase Activity Colorimetric Assay Kit Guide
2026-09-01
Measure functional aconitase activity alongside immune-cell activation, mitochondrial stress, or cytotoxicity endpoints. This workflow shows how a rapid 450 nm colorimetric readout can distinguish metabolic remodeling from oxidative loss of enzyme function.
-
Lambda Protein Phosphatase for BMAL1 Assays
2026-09-01
Use Lambda Protein Phosphatase to separate phosphorylation-dependent effects from antibody, abundance, and condensate artifacts in BMAL1 research. This practical guide combines paired dephosphorylation controls, phase-separation workflows, assay optimization, and troubleshooting for more defensible phosphorylation studies.
-
Neuromedin S (rat): GPCR Assay Workflow
2026-08-31
Neuromedin S (rat), SKU B5466, provides a defined rat peptide input for controlled neuromedin U receptor and GPCR/G protein signaling assays. This guide covers reconstitution, assay setup, and quality control while defining the limits of interpretation when no directly matched paper evidence or potency data are available.
-
What AKT Inhibitors Reveal About Drug Activity
2026-08-31
Kostaras and colleagues systematically compared clinical ATP-competitive and allosteric AKT inhibitors using biochemical, cellular, structural, and phosphoproteomic approaches. Their findings show that inhibitor class, AKT isoform, mutation status, and non-catalytic functions can strongly shape drug response, providing a framework for mechanism-informed combination therapy.
-
AZD1390: From ATM Signaling to Assay Design
2026-08-30
AZD1390 is an ATM kinase inhibitor for dissecting DNA damage response signaling, radiation sensitivity, and replication-associated stress. This article develops a fork-centered assay strategy that connects ATM inhibition with REV1–DHX36 control of G-quadruplex DNA without overstating mechanistic evidence.
-
Meropenem Trihydrate in Resistance Phenotyping
2026-08-29
Meropenem trihydrate is a carbapenem antibiotic with value beyond routine susceptibility testing. This article explains how to integrate its mechanism, formulation, and LC-MS/MS metabolomics into more discriminating antibiotic resistance studies.
-
Cefepime (BMY-28142) in Resistance Research
2026-08-28
Use Cefepime (BMY-28142) as a controlled phenotype comparator in carbapenemase and bacterial infection model workflows, with practical extensions into central nervous system infection research. The workflow combines fresh-solution handling, broth microdilution, plasmid-aware interpretation, and neurotoxicity studies without treating research findings as clinical guidance.
-
Olaparib Nanoparticles in a Sprayable Brain Hydrogel
2026-08-28
McCrorie and colleagues developed a post-surgical delivery platform that combines etoposide and Olaparib nanocrystals with a PLA–PEG coating and a sprayable, brain-bioadhesive pectin hydrogel. The study provides preclinical evidence for formulation stability, controlled release, sprayability, and deposition around a resection cavity, while identifying the additional work needed to establish therapeutic efficacy and clinical transferability.